After weathering failure, rejection and layoffs, ImmunoGen touts a new 'breakthrough' drug in its comeback plan

The FDA has granted breakthrough therapy designation to IMGN632, which targets CD123, in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm. The aggressive cancer primarily affects the skin, bone marrow and lymph nodes.